Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Down 21.9% in January

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 105,482 shares, a decrease of 21.9% from the December 31st total of 135,073 shares. Based on an average daily volume of 47,847 shares, the short-interest ratio is presently 2.2 days. Approximately 2.2% of the company’s shares are sold short. Approximately 2.2% of the company’s shares are sold short. Based on an average daily volume of 47,847 shares, the short-interest ratio is presently 2.2 days.

Analysts Set New Price Targets

EVAX has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research note on Monday, October 20th. Lake Street Capital upped their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Jones Trading raised Evaxion A/S to a “strong-buy” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Finally, Edward Jones started coverage on Evaxion A/S in a research note on Thursday, October 30th. They issued a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Evaxion A/S Stock Down 6.5%

Shares of EVAX stock traded down $0.22 during trading on Friday, hitting $3.18. The company had a trading volume of 76,707 shares, compared to its average volume of 70,052. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The stock has a market capitalization of $26.52 million, a price-to-earnings ratio of -8.15 and a beta of 0.29. The stock’s 50-day moving average is $5.05 and its two-hundred day moving average is $4.53.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.